Neurolief Unveils Proliv®Rx, A Game-Changing At-Home Therapy for Major Depression at APA 2026

Neurolief Showcases Proliv®Rx at APA 2026

Neurolief, Inc., a pioneering medical technology firm, is set to present its innovative therapy, Proliv®Rx, at the APA Annual Meeting from May 16-20, 2026, in San Francisco. This FDA-approved device is designed for adults suffering from Major Depressive Disorder (MDD) who have experienced insufficient relief from traditional antidepressant treatments.

The main objective of Proliv®Rx is to provide an effective, noninvasive treatment option that can be administered at home, under the guidance of a physician. This approach aims to bridge the gap in depression management for individuals who struggle to access specialized care due to geographical or logistical constraints. The therapy involves structured sessions, appropriately monitored to ensure patient safety and adherence to the prescribed regimen.

In a bid to democratize access to advanced mental health treatments, Neurolief will also engage with attendees in the Mental Health Innovation Zone and participate in the Med Buzz Hub, a spotlight for emerging technologies. One of the highlights of their presentation will be a Key Opinion Leader (KOL) panel discussion on May 18, featuring esteemed physicians who will delve into the clinical evidence and operational model supporting Proliv®Rx.

Scott Drees, CEO of Neurolief, articulated the company's mission succinctly: “Many patients don’t see their depression improve with typical treatments, and the roadblocks to receiving alternative therapies can be overwhelming.” Proliv®Rx provides a practical option for these individuals, delivering intervention while under the physician's supervision, but in the comfort of their own homes.

Understanding Proliv®Rx and its Mechanism

The foundation of Proliv®Rx lies in Neurolief's proprietary External Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) technology. This system employs a targeted, multi-channel stimulation approach, engaging specific neural pathways directly associated with depressive symptoms. This is achieved by targeting cranial regions known for their connection to emotional regulation, promoting a potential shift in depressive states effectively.

Evidence from the MOOD pivotal study backs the effectiveness of Proliv®Rx. In this multicenter, randomized trial involving adults with MDD who hadn't benefited from prior antidepressants, results showed that patients experienced significant reductions in depressive symptoms within eight weeks of treatment. With ongoing use, a remarkable 31.7% of participants reached full remission after 16 weeks. The study also confirmed that the therapy was generally well-tolerated, with most side effects being mild and transient.

Dr. Owen Scott Muir, Chief Medical Officer at Neurolief, emphasized the need for clinical validation in current treatment practices: “Proliv®Rx isn't merely an at-home device; it embodies a clinician-guided approach meant to offer a real chance for improvement to patients caught in the cycle of conventional medications. Engaging in the APA Annual Meeting will enable us to share this novel model with psychiatrists.”

Conclusion and Future Directions

In addition to the event activities, Neurolief has launched a new website dedicated to Proliv®Rx, targeted towards clinicians, healthcare systems, and patients alike. This digital platform aims to offer comprehensive insights into the therapy, its clinical underpinnings, and the overarching supervised care model.

Neurolief stands at the forefront of redefining how Major Depressive Disorder is approached, as it strives to make essential therapies more accessible, supporting a health system in dire need of effective solutions beyond conventional outpatient clinic settings. With Proliv®Rx and a dedicated commitment to innovation in mental health, the company is poised to make a significant impact on the landscape of depression treatment.

For anyone grappling with MDD, the upcoming APA Annual Meeting will be a focal point for understanding advanced treatment modalities and the potential for life-changing interventions like Proliv®Rx.